<qa>  What is the primary endpoint of the study?This study is randomized, Sodium Ozagrel Thromboxane A2 Synthase Inhibitor controlled study on acute ischemic stroke. The primary endpoints were the rate of patients with modified Rankin Scale score of 0-1 at 3 months. 